$-0.04
(Market cap
$0 Mln
Recently Viewed
Clear AllMarket cap
$0 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-5.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.1
Debt to Equity
0
Book Value
$--
EPS
$-1.9
Face value
--
Shares outstanding
42,372,260
CFO
$-37.04 Mln
EBITDA
$-47.56 Mln
Net Profit
$-97.65 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Petros Pharmaceuticals (PTPI)
| -- | -- | -- | -99.5 | -96.3 | -90.6 | -- |
|
BSE Sensex
| -7.8 | 4.8 | -6.3 | 3.9 | 8.9 | 10.0 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Petros Pharmaceuticals (PTPI)
| -71.8 | -39.5 | -93.0 | -24.3 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Petros Pharmaceuticals (PTPI)
|
0.0 | 0.2 | 0.7 | -7.0 | -2,026.9 | -- | -- | 0.1 |
| 69.5 | 8,932.7 | 1,091.0 | 202.3 | 31.6 | 31.3 | 39.9 | 16.0 | |
| 65.5 | 8,217.4 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.1 | 12,054.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 85.9 | 10,783.5 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 266.6 | 7,871.4 | 389.1 | 204.8 | 41.5 | 18.9 | 39 | 6.5 | |
| 518.7 | 12,058.9 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.8 | |
| 518.8 | 14,314.2 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.8 | 30.7 | |
| 104.4 | 8,151.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.5 | |
| 337.9 | 8,828.7 | 0.0 | -303.3 | -- | -45.8 | -- | 10.0 |
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New... York, New York. Read more
Executive Chairman of the Board
Mr. John David Shulman
Executive Chairman of the Board
Mr. John David Shulman
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Petros Pharmaceuticals Inc (PTPI) is $0.01 (NASDAQ) as of 15-Apr-2026 09:41 EDT. Petros Pharmaceuticals Inc (PTPI) has given a return of -96.3% in the last 3 years.
Since, TTM earnings of Petros Pharmaceuticals Inc (PTPI) is negative, P/E ratio is not available.
The P/B ratio of Petros Pharmaceuticals Inc (PTPI) is 0.07 times as on 10-Apr-2026, a 98 discount to its peers’ median range of 4.32 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-2.21
|
-4.23
|
|
2023
|
-0.52
|
0.34
|
|
2022
|
-0.24
|
0.29
|
|
2021
|
-0.53
|
0.13
|
|
2020
|
-0.24
|
0.28
|
The 52-week high and low of Petros Pharmaceuticals Inc (PTPI) are Rs 10.56 and Rs 0.01 as of 16-Apr-2026.
Petros Pharmaceuticals Inc (PTPI) has a market capitalisation of $ 0 Mln as on 10-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Petros Pharmaceuticals Inc (PTPI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.